

### Online Resource 3

**Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy**

**Journal:** Breast Cancer Research and Treatment

**Authors:** A.F. de Groot<sup>1</sup>, E.J. Blok<sup>1,2</sup>, A. Charehbili<sup>1,2</sup>, C.C. Engels<sup>2</sup>, V.T.H.B.M. Smit<sup>3</sup>, N.G. Dekker-Ensink<sup>2</sup>, H. Putter<sup>4</sup>, E. Meershoek - Klein Kranenbarg<sup>2</sup>, C.J.H. van de Velde<sup>2</sup>, G.J. Liefers<sup>2</sup>, J.W.R. Nortier<sup>1</sup>, P.J.K. Kuppen<sup>2</sup>, S.H. van der Burg<sup>1</sup>, J.R. Kroep<sup>1</sup>

Departments of Medical Oncology<sup>1</sup>, Surgery<sup>2</sup>, Pathology<sup>3</sup>, Statistics<sup>4</sup>, Leiden University Medical Center, Leiden, The Netherlands

**Corresponding author:** Judith R. Kroep, M.D., Ph.D. ([j.r.kroep@lumc.nl](mailto:j.r.kroep@lumc.nl))

**Online Resource 3** Response (pCR) to chemotherapy **a** Stratified on immune markers and **b** Based on immune markers, stratified on HLA class 1 status

**a**

		No pCR		pCR		Total	P-value
		N	%	N	%	N	
<b>CD8+ CTLs by median</b>	Low (< median)	73	94.8%	4	5.2%	153	0.01
	High (> median)	62	81.6%	14	18.4%		
<b>FoxP3+ Tregs by median</b>	Low (< median)	71	91.0%	7	9.0%	150	0.49
	High (> median)	63	87.5%	9	12.5%		
<b>CD68+ TAMs by median</b>	Low (< median)	70	88.6%	9	11.4%	157	0.98
	High (> median)	69	88.5%	9	11.5%		
<b>HLA class 1 status</b>	Loss or downregulation	56	96.6%	2	3.4%	171	0.03
	Expression	97	85.8%	16	14.2%		

**b**

		HLA class 1 status											
		Loss or downregulation						Expression					
		No pCR		pCR		Total	P-value	No pCR		pCR		Total	P-value
		N	%	N	%	N		N	%	N	%	N	
<b>CD8+ CTLs by median</b>	Low (< median)	28	100.0%	0	0.0%	45	0.38	42	93.3%	3	6.7%	100	0.04
	High (> median)	16	94.1%	1	5.9%			43	78.2%	12	21.8%		
<b>FoxP3+ Tregs by median</b>	Low (< median)	34	94.4%	2	5.6%	49	1.00	33	89.2%	4	10.8%	96	0.54
	High (> median)	13	100.0%	0	0.0%			50	84.7%	9	15.3%		
<b>CD68+ TAMs by median</b>	Low (< median)	22	100.0%	0	0.0%	42	0.48	47	85.5%	8	14.5%	106	0.90
	High (> median)	19	95.0%	1	5.0%			44	86.3%	7	13.7%		

Loss or downregulation of HLA class 1 is defined as <5% of tumor cells staining positive for HCA2 and HC10 (loss), or either HCA2 or HC10 (downregulation).

Expression of HLA class 1 is defined as ≥5% of tumor cells staining positive for HCA2 and HC10. P-values represent Chi-square or Fisher's exact tests. *CTLs* cytotoxic

T-cells, *pCR* pathological complete response, *TAMs* tumor-associated macrophages, *Tregs* regulatory T-cells